Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) --  Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced the appointment of Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6, 2026. The Company also announced that Elliott Levy, M.D., will step down from the Board and his role as an independent director.
        
Dr. Ellinor has dedicated his career to advancing the understanding of cardiovascular disease through human genetics. His research has helped identify novel therapeutic targets for cardiovascular disease and advance the translation of discoveries in human genetics toward potential new therapies. Throughout his career, he has combined pioneering research with clinical leadership and extensive collaborations across academia and industry to accelerate the development of innovative medicines for patients.